Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors

Journal of the American College of Cardiology

Volumn 66, Issue 10, 2015, Pages 1160-1178

  Li, Weijuan ^a   Croce, Kevin ^b   Steensma, David P ^c   McDermott, David F ^b   Ben Yehuda, Ori ^d   Moslehi, Javid ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

cardio oncology; metabolic toxicity; vascular toxicity

Indexed keywords

AFLIBERCEPT; APATINIB; AXITINIB; BEVACIZUMAB; CABOZANTINIB; DASATINIB; IDELALISIB; LENVATINIB; LUCITANIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; NILOTINIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PONATINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; PROTEIN KINASE INHIBITOR;

AGE; ANGIOGENESIS; ARTERY THROMBOSIS; CANCER GRADING; CANCER THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; KIDNEY FAILURE; META ANALYSIS (TOPIC); METABOLIC DISORDER; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STENT THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; VEIN THROMBOSIS; ANIMAL; CARDIOVASCULAR SYSTEM; DISEASE MODEL; DRUG EFFECTS; FEMALE; MALE; MORTALITY; NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84940569058     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.07.025     Document Type: Review

References (128)

1. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 2009 28 39
2. T. Force, and K.L. Kolaja Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat Rev Drug Discov 10 2011 111 126
3. D.R. Shah, R.R. Shah, and J. Morganroth Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy Drug Saf 36 2013 413 426
4. H. Ahmadieh, and I. Salti Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment Biomed Res Int 2013 2013 725410
5. D. Fabbro, S.W. Cowan-Jacob, H. Mobitz, and G. Martiny-Baron Targeting cancer with small-molecular-weight kinase inhibitors Methods Mol Biol 795 2012 1 34
6. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N Engl J Med 353 2005 172 187
7. H. Eyre, R. Kahn, R.M. Robertson, and et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Stroke 35 2004 1999 2010
8. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed July 31, 2015.
9. J.D. Groarke, S. Cheng, and J. Moslehi Cancer-drug discovery and cardiovascular surveillance N Engl J Med 369 2013 1779 1781
10. K.A. Hicks, J.E. Tcheng, B. Bozkurt, and et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) J Am Coll Cardiol 66 2015 403 469
11. B.M. Scirica, D.L. Bhatt, E. Braunwald, and et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
12. N. de Jesus-Gonzalez, E. Robinson, J. Moslehi, and B.D. Humphreys Management of antiangiogenic therapy-induced hypertension Hypertension 60 2012 607 615
13. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803
14. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
15. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 2011 298 307
16. A. Hoeben, B. Landuyt, M.S. Highley, and et al. Vascular endothelial growth factor and angiogenesis Pharmacol Rev 56 2004 549 580
17. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974
18. J.D. Groarke, T.K. Choueiri, D. Slosky, and et al. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway Curr Treat Options Cardiovasc Med 16 2014 335
19. M.L. Maitland, K.E. Kasza, T. Karrison, and et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Clin Cancer Res 15 2009 6250 6257
20. M. Azizi, A. Chedid, and S. Oudard Home blood-pressure monitoring in patients receiving sunitinib N Engl J Med 358 2008 95 97
21. J. Cai, H. Ma, F. Huang, and et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis World J Surg Oncol 11 2013 306
22. S.P. Gampenrieder, F. Romeder, C. Muss, and et al. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis Anticancer Res 34 2014 227 233
23. S. George, P. Reichardt, T. Lechner, and et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib Ann Oncol 23 2012 3180 3187
24. B.I. Rini, D.P. Cohen, D.R. Lu, and et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
25. C.C. Wagner, U. Held, R. Kofmehl, and et al. Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis Acta Oncol 53 2014 572 575
26. Z.F. Zhang, T. Wang, L.H. Liu, and H.Q. Guo Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis PLoS One 9 2014 e90135
27. J.C. Yang, L. Haworth, R.M. Sherry, and et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
28. K.D. Miller, L.I. Chap, F.A. Holmes, and et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 2005 792 799
29. D.D. Ku, J.K. Zaleski, S. Liu, and T.A. Brock Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries Am J Physiol 265 1993 H586 H592
30. J.D. Hood, C.J. Meininger, M. Ziche, and H.J. Granger VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol 274 1998 H1054 H1058
31. Y. Wang, D. Fei, M. Vanderlaan, and A. Song Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 2004 335 345
32. M.H. Kappers, J.H. van Esch, W. Sluiter, and et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels Hypertension 56 2010 675 681
33. T. Inai, M. Mancuso, H. Hashizume, and et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am J Pathol 165 2004 35 52
34. V. Eremina, S. Cui, H. Gerber, and et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival J Am Soc Nephrol 17 2006 724 735
35. T. Chaiworapongsa, P. Chaemsaithong, L. Yeo, and R. Romero Pre-eclampsia part 1: current understanding of its pathophysiology Nat Rev Nephrol 10 2014 466 480
36. T.V. Patel, J.A. Morgan, G.D. Demetri, and et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib J Natl Cancer Inst 100 2008 282 284
37. A. Luttun, and P. Carmeliet Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 111 2003 600 602
38. V. Eremina, J.A. Jefferson, J. Kowalewska, and et al. VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 2008 1129 1136
39. C. Vigneau, N. Lorcy, T. Dolley-Hitze, and et al. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study Nephrol Dial Transplant 29 2014 325 332
40. M.L. Maitland, G.L. Bakris, H.R. Black, and et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
41. X.F. Hang, W.S. Xu, J.X. Wang, and et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials Eur J Clin Pharmacol 67 2011 613 623
42. Y. Je, F.A. Schutz, and T.K. Choueiri Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Lancet Oncol 10 2009 967 974
43. A.M. Byrne, D.J. Bouchier-Hayes, and J.H. Harmey Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J Cell Mol Med 9 2005 777 794
44. P. Ferroni, V. Formica, M. Roselli, and F. Guadagni Thromboembolic events in patients treated with anti-angiogenic drugs Curr Vasc Pharmacol 8 2010 102 113
45. T. Meyer, L. Robles-Carrillo, T. Robson, and et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice J Thromb Haemost 7 2009 171 181
46. U. Schraermeyer, and S. Julien Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye Graefes Arch Clin Exp Ophthalmol 250 2012 1303 1313
47. F.A. Scappaticci, J.R. Skillings, S.N. Holden, and et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
48. N.B. Leighl, J. Bennouna, J. Yi, and et al. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study Br J Cancer 104 2011 413 418
49. N.M. Agostino, V.M. Chinchilli, C.J. Lynch, and et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice J Oncol Pharm Pract 17 2011 197 202
50. A. Fountas, S. Tigas, Z. Giotaki, and et al. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment Hormones (Athens) 2014 Dec 29 [E-pub ahead of print]
51. Y. Lee, H.S. Jung, H.J. Choi, and et al. Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report Diabetes Res Clin Pract 93 2011 e68 70
52. A. Templeton, M. Brandle, T. Cerny, and S. Gillessen Remission of diabetes while on sunitinib treatment for renal cell carcinoma Ann Oncol 19 2008 824 825
53. C. Louvet, G.L. Szot, J. Lang, and et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proc Natl Acad Sci U S A 105 2008 18895 18900
54. U. Rix, O. Hantschel, G. Durnberger, and et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110 2007 4055 4063
55. H. Kantarjian, E. Jabbour, J. Grimley, and et al. Dasatinib Nat Rev Drug Discov 5 2006 717 718
56. J.E. Cortes, H. Kantarjian, N.P. Shah, and et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2012 2075 2088
57. H. Kantarjian, N.P. Shah, A. Hochhaus, and et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
58. G. Saglio, D.W. Kim, S. Issaragrisil, and et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
59. S. Masuda, K. Nakano, K. Funakoshi, and et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries J Atheroscler Thromb 18 2011 1043 1053
60. M. Lassila, T.J. Allen, Z. Cao, and et al. Imatinib attenuates diabetes-associated atherosclerosis Arterioscler Thromb Vasc Biol 24 2004 935 942
61. F.J. Giles, M.J. Mauro, F. Hong, and et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis Leukemia 27 2013 1310 1315
62. H.A. Ghofrani, W. Seeger, and F. Grimminger Imatinib for the treatment of pulmonary arterial hypertension N Engl J Med 353 2005 1412 1413
63. D. Montani, E. Bergot, S. Gunther, and et al. Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 2012 2128 2137
64. Young-Woo Jeon S-EL, Soo-Hyun Kim, et al. Six-year follow-up of dasatinib-related pulmonary arterial hypertension (PAH) for chronic myeloid leukemia in single center. Paper presented at: 55th ASH Annual Meeting and Exposition; December 7-10, 2013; New Orleans, LA.
65. H. de Lavallade, S. Punnialingam, D. Milojkovic, and et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis Br J Haematol 141 2008 745 747
66. A. Bergeron, D. Rea, V. Levy, and et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series Am J Respir Crit Care Med 176 2007 814 818
67. P. Le Coutre, D. Rea, E. Abruzzese, and et al. Severe peripheral arterial disease during nilotinib therapy J Natl Cancer Inst 103 2011 1347 1348
68. A. Tefferi, and L. Letendre Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia Am J Hematol 86 2011 610 611
69. K.J. Aichberger, S. Herndlhofer, G.H. Schernthaner, and et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML Am J Hematol 86 2011 533 539
70. A. Quintas-Cardama, H. Kantarjian, and J. Cortes Nilotinib-associated vascular events Clin Lymphoma Myeloma Leuk 12 2012 337 340
71. R.A. Larson, A. Hochhaus, T.P. Hughes, and et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up Leukemia 26 2012 2197 2203
72. T.D. Kim, D. Rea, M. Schwarz, and et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib Leukemia 27 2013 1316 1321
73. H.M. Kantarjian, F. Giles, N. Gattermann, and et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546
74. P. le Coutre, O.G. Ottmann, F. Giles, and et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Blood 111 2008 1834 1839
75. Z. Racil, F. Razga, J. Drapalova, and et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia Haematologica 98 2013 e124 e126
76. T. Yoshizato, Y. Nannya, Y. Yoshiki, and et al. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia Int J Hematol 93 2011 400 402
77. J.E. Cortes, D.W. Kim, J. Pinilla-Ibarz, and et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias N Engl J Med 369 2013 1783 1796
78. Hagop M, Kantarjian D-WK, Pinilla-Ibarz J, et al. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial. Paper presented at: 50th ASCO Annual Meeting; May 30 to June 3, 2014; Chicago, IL.
79. FDA Approval for Ponatinib Hydrochloride with safety announcement. Available at: http://www.cancer.gov/about-cancer/treatment/drugs/fda-ponatinibhydrochloride. Accessed July 31, 2015.
80. C.P. Loren, J.E. Aslan, R.A. Rigg, and et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear Thromb Res 135 2015 155 160
81. K.E. Price, N. Saleem, G. Lee, and M. Steinberg Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia Onco Targets Ther 6 2013 1111 1118
82. J.C. Uitdehaag, J.A. de Roos, A.M. van Doornmalen, and et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use PLoS One 9 2014 e92146
83. S. Branford, D.T. Yeung, W.T. Parker, and et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline Blood 124 2014 511 518
84. C. Gambacorti-Passerini, L. Antolini, F.X. Mahon, and et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib J Natl Cancer Inst 103 2011 553 561
85. P. Valent, E. Hadzijusufovic, G.H. Schernthaner, and et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors Blood 125 2015 901 906
86. J. Polivka Jr., and F. Janku Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway Pharmacol Ther 142 2014 164 175
87. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, and et al. The emerging mechanisms of isoform-specific PI3K signalling Nat Rev Mol Cell Biol 11 2010 329 341
88. T. Aoyagi, and T. Matsui Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure Curr Pharm Des 17 2011 1818 1824
89. M.A. Crackower, G.Y. Oudit, I. Kozieradzki, and et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways Cell 110 2002 737 749
90. J.R. McMullen, and P.Y. Jay PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart Cell Cycle 6 2007 910 913
91. G.Y. Oudit, M.A. Crackower, U. Eriksson, and et al. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure Circulation 108 2003 2147 2152
92. X. Song, Y. Kusakari, C.Y. Xiao, and et al. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy Am J Physiol Cell Physiol 299 2010 C1256 C1266
93. C.M. Taniguchi, B. Emanuelli, and C.R. Kahn Critical nodes in signalling pathways: insights into insulin action Nat Rev Mol Cell Biol 7 2006 85 96
94. L.C. Foukas, M. Claret, W. Pearce, and et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation Nature 441 2006 366 370
95. M. Fraenkel, M. Ketzinel-Gilad, Y. Ariav, and et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes Diabetes 57 2008 945 957
96. F.B. Kraemer, D. Takeda, V. Natu, and C. Sztalryd Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways Metabolism 47 1998 555 559
97. R.J. Motzer, B. Escudier, S. Oudard, and et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
98. G. Hudes, M. Carducci, P. Tomczak, and et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
99. Idelalisib was approved by FDA. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm. Accessed July 31, 2015.
100. N.L. Busaidy, A. Farooki, A. Dowlati, and et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway J Clin Oncol 30 2012 2919 2928
101. K. Thygesen, J.S. Alpert, A.S. Jaffe, and et al. Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
102. T.M. Guest, A.V. Ramanathan, P.G. Tuteur, and et al. Myocardial injury in critically ill patients: A frequently unrecognized complication JAMA 273 1995 1945 1949
103. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
104. M.P. Bonaca, B.M. Scirica, M.A. Creager, and et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50 Circulation 127 2013 1522 1529 1529e1-6
105. V. Ranpura, B. Pulipati, D. Chu, and et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis Am J Hypertens 23 2010 460 468
106. W.X. Qi, F. Lin, Y.J. Sun, and et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis Cancer Chemother Pharmacol 71 2013 431 439
107. X. Zhu, K. Stergiopoulos, and S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 2009 9 17
108. T. Funakoshi, A. Latif, and M.D. Galsky Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis J Hum Hypertens 27 2013 601 611
109. W.X. Qi, A.N. He, Z. Shen, and Y. Yao Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis Br J Clin Pharmacol 76 2013 348 357
110. W.X. Qi, Z. Shen, F. Lin, and et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials Br J Clin Pharmacol 75 2013 919 930
111. Z. Wang, J. Xu, W. Nie, and et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis Eur J Clin Pharmacol 70 2014 225 231
112. R. Elisei, M.J. Schlumberger, S.P. Muller, and et al. Cabozantinib in progressive medullary thyroid cancer J Clin Oncol 31 2013 3639 3646
113. W.X. Qi, Z. Shen, L.N. Tang, and Y. Yao Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis Clin Drug Investig 34 2014 231 240
114. J. Wang, Z. Wang, and Y. Zhao Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies Clin Drug Investig 35 2015 221 228
115. J.C. Soria, F. DeBraud, R. Bahleda, and et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Ann Oncol 25 2014 2244 2251
116. M. Schlumberger, M. Tahara, L.J. Wirth, and et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer N Engl J Med 372 2015 621 630
117. J. Li, S. Qin, J. Xu, and et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial J Clin Oncol 31 2013 3219 3225
118. X. Hu, J. Cao, W. Hu, and et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer BMC Cancer 14 2014 820
119. X. Hu, J. Zhang, B. Xu, and et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer Int J Cancer 135 2014 1961 1969
120. S.R. Nalluri, D. Chu, R. Keresztes, and et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
121. V. Ranpura, S. Hapani, J. Chuang, and S. Wu Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials Acta Oncol 49 2010 287 297
122. G. Sonpavde, Y. Je, F. Schutz, and et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials Crit Rev Oncol Hematol 87 2013 80 89
123. W.X. Qi, Z. Shen, L.N. Tang, and Y. Yao Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis Crit Rev Oncol Hematol 92 2014 71 82
124. T.K. Choueiri, F.A. Schutz, Y. Je, J.E. Rosenberg, and J. Bellmunt Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
125. A. Grothey, E. Van Cutsem, A. Sobrero, and et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
126. G.D. Demetri, P. Reichardt, Y.K. Kang, and et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 295 302
127. E. Van Cutsem, J. Tabernero, R. Lakomy, and et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
128. H. Wilke, K. Muro, E. Van Cutsem, and et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 2014 1224 1235